###### Key messages

What is already known about this subject?
=========================================

-   Interleukin (IL)-23-producing myeloid cells are thought to be key to the pathogenesis of closely related disease such as psoriasis and inflammatory bowel disease.

-   The enthesis is considered the cardinal lesion in psoriatic arthritis (PsA) and spondyloarthropathy (SpA) but it was previously unknown if this tissue contained a population of myeloid cells capable of IL-23 production.

-   It has been considered that intestinal or systemically derived IL-23 may have been responsible for triggering enthesitis.

What does this study add?
=========================

-   We demonstrate that normal spinal enthesis soft tissue and bone has resident myeloid cells.

-   It was possible to induce IL-23 protein which was almost exclusive to a population of CD14+ myeloid cells.

How might this impact on clinical practice or future developments?
==================================================================

-   This study increases the understanding of innate immunity at the normal healthy human enthesis that needs further study to understand how this might contribute to blocking IL-23 efficacy, or not in some settings, in PsA and SpA.

Introduction {#s1}
============

Synovitis is the primary lesion in rheumatoid arthritis (RA), whereas in spondyloarthropathy (SpA)-related diseases, enthesitis is the cardinal lesion.[@R1] Psoriatic arthritis (PsA) and the associated SpA disorders are linked to multiple genetic polymorphisms in the interleukin (IL)-23/17 axis. Manipulation of this pathway results in an enthesitis-dependent murine arthritis and several populations of IL-23R positive cells reside at the normal murine and human enthesis.[@R1] The observed difference in efficacy of IL-23/17 axis blockers and phosphodiesterase 4 inhibitor (PDE4I) therapy in RA and SpA may be a result of immunopathogenic differences linked to the location of the primary site of inflammation.[@R1]

The prevailing theories have proposed that the IL-23 driving enthesitis originates at remote sites including the gut.[@R3] In both human psoriasis and mouse models of psoriasis, the major producers of IL-23 are skin resident myeloid cells.[@R7] Studies also implicate myeloid cells in human enthesitis with macrophages being present in early SpA-related enthesitis.[@R8] A recent mouse model of mechanical strain also confirmed enthesitis was dependent on myeloid infiltration.[@R9]

Accordingly, we hypothesised that the human enthesis harbours a population of myeloid cells capable of proinflammatory cytokine production. We investigated whether potential IL-23 secretion could be modulated by PDE4 inhibition, a target pathway known to show efficacy in PsA but not RA.

Materials and methods {#s2}
=====================

Comprehensive materials and methods can be found in [online supplementary material](#SP1){ref-type="supplementary-material"}s. Briefly, for tissue collection, normal spinous process enthesis was obtained from 15 patients (6 men and 9 women; median age 46 years) who were undergoing spinal decompression or surgery for scoliosis correction of thoracic or lumbar vertebrae using previously described methods[@R4] (see [online supplementary figure 1](#SP1){ref-type="supplementary-material"}). The study protocol of the current investigation was approved by North West-Greater Manchester West Research Ethics Committee.
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Statistical analysis {#s2-1}
--------------------

Statistical significance was calculated using a one or two-way analysis of variance with Bonferroni\'s multiple comparisons test, unless stated. Analysis was performed using Prism software (GraphPad software V.8.0, La Jolla, CA, USA). Error bars represent the SEM.

Results {#s3}
=======

Myeloid cells are present in entheseal soft tissue and bone and can produce IL-23 {#s3-1}
---------------------------------------------------------------------------------

Following the digestion of both the perientheseal bone (PEB) and soft tissue (ST) enthesis and flow cytometry analysis, a myeloid CD45+ CD14+ HLADR+ CD11c+ (hereafter referred to as the CD14+ population) and a CD45+ CD14− (hereafter referred to as the CD14− population) of cells were evident (see [online supplementary figures 2--4](#SP1){ref-type="supplementary-material"}). Within the CD14− fraction, a CD123+HLADR+ CD11c− (plasmacytoid dendritic cell) population was identified, accounting for 1% of CD45+ cells ([online supplementary figure 2](#SP1){ref-type="supplementary-material"}). Due to demands of using multiple colours for flow cytometry, we decided to exclude the analysis of ILC3 cells, which we have previously identified at the human enthesis.[@R4] Histological staining of both the PEB and ST showed CD14+ enthesis immune cell populations ([figure 1A, B](#F1){ref-type="fig"}). For control staining and isotype control, see [online supplementary figure 5](#SP1){ref-type="supplementary-material"}.

![Immunohistochemistry of CD14+ cells in (A) perientheseal bone (PEB) and (B) entheseal soft tissue (ST). Enthesis samples were separated into PEB and ST and CD14+ and CD14− cells sorted. (C--J) CD14+ and CD14− fractions were stimulated with LPS/interferon gamma (IFNү) or mannan for 48 hours. TNF, IL-23, CCL20 and IL-1β levels were measured by ELISA. n=5. Two-way analysis of variance (ANOVA) with Bonferroni multiple comparisons test was performed. \*Significance from relevant unstimulated control, for example, CD14+ or CD14− unstimulated. (K) PEB was stimulated with LPS/IFNү in the presence of Golgi plug for 16 hours. Cells were surface stained for CD14+ and CD14− cells and intracellular IL-23p19 were measured. Blue histograms represent unstimulated and red stimulated. (L) Change in IL-23p19 median fluorescence intensity (MFI), following LPS/IFNү stimulation in both CD14+ and CD14− gates. n=3. Paired t-test. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001. IL, interleukin; LPS, lipopolysaccharide; PEB, perientheseal bone; ST, soft tissue; TNF-α, tumour necrosis factor alpha.](annrheumdis-2018-214944f01){#F1}

Following the isolation of CD14+ and CD14− fractions by fluorescence-activated cell sorting (FACS), they were stimulated with either mannan or lipopolysaccharide (LPS) and interferon gamma (IFNγ). Disease-relevant cytokines and chemokines, tumour necrosis factor (TNF), IL-23 (full protein p40+p19), CCL20 and IL-1β were measured by ELISA ([figure 1C--J](#F1){ref-type="fig"}). IL-23 and CCL20 were only inducible from CD14+ cells (red box plots) following stimulation ([figure 1E--H](#F1){ref-type="fig"}). While both fractions CD14+ and CD14− showed inducible TNF and IL-1β following stimulation, this was only statistically significant in the CD14+ fraction ([figure 1C, D, I, J](#F1){ref-type="fig"}).

In terms of weight, the PEB contained more CD14+ per gram than the ST (mean=7.9×10^4^ vs 6.8×10^3^). Because of the scarcity of available cells in the ST, CD14+ and CD14− cells were seeded at a lower density than those from the bone (see the Materials and methods section). The individual CD14+ myeloid cell production of IL-23 and TNF expressed as pg/cell was not significantly different between PEB and ST ([online supplementary figure 6](#SP1){ref-type="supplementary-material"}). Intracellular staining for IL-23 of both CD14+ and CD14− populations following LPS/IFNγ stimulation also confirmed CD14+ as the exclusive IL-23 producer in the PEB ([figure 1K, L](#F1){ref-type="fig"}).

PDE4I and other cAMP-elevating agents inhibit IL-23 from CD14+ entheseal and blood myeloid cells {#s3-2}
------------------------------------------------------------------------------------------------

From [figure 1](#F1){ref-type="fig"}, it was evident that CD14+ cells were the exclusive IL-23 producers. We next tested the ability of a PDE4I (rolipram) to modulate IL-23 secretion. Rolipram is widely used *in vitro* to study the effects of PDE4 inhibition and has a similar profile to apremilast.[@R10] Blockade of the PDE4 pathway is efficacious in PsA but not RA. Rolipram effectively inhibited both mannan/IFNγ and LPS/IFNγ-induced IL-23 and TNF from the CD14+ fraction from both ST and PEB ([figure 2A--D](#F2){ref-type="fig"}).

![(A--D) CD14+ fraction cells were isolated from the PEB and ST as before (n=5), and stimulated with LPS/IFNү and mannan as before, with and without PDE4I rolipram, IL-23 and TNF were measured by ELISA. (E, F) Healthy blood CD14+ cells were stimulated with LPS/IFNү (E) or mannan (F) with and without cAMP-elevating agents; rolipram, 8-Br-cAMP and histamine for 48 hours (n=7), IL-23 secretion was measured by ELISA. One-way analysis of variance (ANOVA) with Bonferroni multiple comparisons test was performed. (E, F) Significance from stimulated (LPS or mannan). (G) CD14+ cells were isolated from the PEB or matched blood and transcript analysis was performed (n=4). Black bars represent those higher expressed in blood, white bars those with higher expression in PEB. Genes highlighted in blue were undetectable in both blood and PEB. A paired t-test was performed on ΔCt values for PEB versus blood. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001. IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; PEB, perientheseal bone; ST, soft tissue; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.](annrheumdis-2018-214944f02){#F2}

PDE4Is are thought to modulate inflammatory pathways via elevating cAMP. Due to the low number of cells yielded from the enthesis, cAMP pathway exploratory research on IL-23 secretion was conducted on the corresponding CD14+ population in blood from healthy donors. CD14+ cells were isolated by FACS and stimulated with LPS/IFNγ ([figure 2E](#F2){ref-type="fig"}) or mannan/IFNγ ([figure 2F](#F2){ref-type="fig"}) as before. To access the importance of the cAMP pathway in PDE4I attenuation of IL-23 production, other molecules known to activate the cAMP pathway (histamine and 8-Bromo-cAMP) were tested for their ability to inhibit IL-23 secretion and confirm the importance of the PDE4 pathway on these cells ([figure 2E, F](#F2){ref-type="fig"}).

Entheseal myeloid cells share a similar gene profile to matched blood cells {#s3-3}
---------------------------------------------------------------------------

In order to provide further functional characterisation of CD14+ myeloid cells in the enthesis, entheseal cells were compared with those isolated from matched blood ([figure 2G](#F2){ref-type="fig"}). Both populations had a broadly similar gene expression profile. The majority of genes analysed did not have a greater than twofold difference and only CCR2 expression was statistically significant ([figure 2G](#F2){ref-type="fig"}). However, the majority of inflammatory cytokines and inflammatory signalling pathways trended higher in the blood population.

Discussion {#s4}
==========

In this study, we report that both normal entheseal ST and adjacent bone have a population of CD45+ CD14+ HLDR+ CD11c+ myeloid cells. Entheseal CD14+ cells are capable of producing IL-23, TNF, IL-1β and CCL20. Moreover, IL-23 and TNF induction can be reduced by PDE4 inhibition. These observations may also be of relevance to disease, given that both PDE4 inhibitors and IL-23 blockers show efficacy in PsA but not RA.

In a landmark IL-23-dependent enthesitis mouse model of SpA, it was shown that in vivo hepatic expression of IL-23 induced enthesitis via an effect on resident enthesis T cells and it was considered that the IL-23 effect was via systemically released cytokine.[@R3] Presently, there are no reports of normal enthesis myeloid cells with the ability to secrete IL-23 locally. Herein we show that cells capable of producing IL-23 are present at the enthesis and that virtually all of the IL-23 was from the CD14+ fraction as opposed to the CD14− fraction. This highlights the potential importance of this myeloid cell population in disease initiation. Both bacterial and fungal adjuvants were able to induce IL-23 production from the CD14+ fraction. In agreement with this, in the SKG mouse model of arthritis where pathology originates as enthesitis, both curdlan and chlamydia promote disease.[@R11] Moreover, previous research has shown myeloid cells such as macrophages in the early inflamed SpA enthesis.[@R8]

It was previously unknown if IL-23-producing myeloid cells at the enthesis were resident or tissue infiltrating. Classification of myeloid cell subsets within tissues is notoriously difficult and remains controversial. A new single-cell RNA-seq approach may be the only way to truly define the myeloid subsets.[@R13] During inflammation, classical monocytes (defined as CD14high CD16low) enter tissues in a CCR2-CCL2 dependent manner. In a recent mouse model of biomechanical loading, arthritis was dependent on CCL2 production and subsequent monocyte recruitment.[@R9] The myeloid cells we described at the enthesis may be non-classical monocytes. It is known that non-classical monocytes migrate and 'patrol' peripheral tissues, so are not defined as tissue resident macrophages in the sense of microglial or Kupffer cells.[@R14] Non-classical monocytes (defined as CD14low CD16high) are known to express less CCR2 and inflammatory mediators when compared with classical monocytes, which would align with our findings.[@R14] Entheseal myeloid cells in our study indeed showed statistically significantly less expression of CCR2, while basal production of inflammatory mediators such as IL-1β, IL-6 and TNF trended downwards.

We also report that fungal and bacterial adjuvants are able to induce CCL20 from enthesis CD14+ cells, but not CD14-- cells. CCL20 is a chemokine that attracts IL-17-expressing cells via its ligand CCR6. In agreement with this, PsA synovial fluid levels of CCL20 correlate with disease severity.[@R15] IL-17-expressing ILC3 and T cells are also CCR6+ from the synovial fluid of patients with PsA.[@R16] These findings suggest a link between enthesis myeloid cells and the cells that preferentially accumulate in the adjacent joint cavity in PsA.

While therapeutic blockage of IL-23 has demonstrated efficacy in PsA, recent results from a clinical trial in patients with ankylosing spondylitis have proved disappointing.[@R18] It has been hypothesised that variation in efficacy may be due to a differing immunopathogenesis including different immune cell populations between the spine and peripheral joint.[@R19] A recent paper using an HLA-B27 rat model showed that SpA pathology is dependent on IL-23 for initiation but not disease persistence.[@R20] This may indeed point towards the idea of IL-17 independent of IL-23 for disease progression, while IL-23 is required for disease initiation. Related research has shown that torn supraspinatus tendon contains IL-17+ cells including T cells; however, it is not known if these cells can produce IL-17 independently of IL-23.[@R21]

PDE4Is are thought to mediate anti-inflammatory effects by elevating cAMP. Other cAMP pathway activators such as histamine and 8-Bromo-cAMP are known to attenuate inflammatory cytokine production from peripheral blood mononuclear cells; however, this is the first report showing this on tissue myeloid cells.[@R22] Previous research has suggested cAMP-elevating agents downregulate IL-12p40, the common chain between IL-12 and IL-23, which in theory may also account for the downregulation of full IL-23 protein (p19+p40) observed ([figure 2A--D](#F2){ref-type="fig"}).[@R22] Further work is required to decipher the exact mechanisms in which cAMP elevation regulates individual IL-12 family member chains.

In conclusion, these data demonstrate that the normal enthesis contains a population of myeloid cells capable of local innate cytokine production including TNF and IL-23. While CD14+ HLADR+ CD11c+ confirm the presence of a myeloid phenotype, further work is required to fully characterise this population. The *in vivo* triggers of myeloid-derived TNF and IL-23 remain to be fully elucidated but our findings show that the normal enthesis contains myeloid cells capable of locally contributing to disease.
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